Literature DB >> 22402011

Primary bone lymphoma.

N G Mikhaeel1.   

Abstract

Primary bone lymphoma is a distinct clinical entity that accounts for 5% of extra-nodal lymphoma. Most patients have diffuse large B-cell lymphoma and present with bone pain, a mass or both. The involvement could be in a single focus or disseminated. There are no prospective clinical studies in this disease. Patients have been treated with radiotherapy, chemotherapy or a combination. There is a trend towards improved outcome with combined modality treatment and further improvement with the addition of rituximab. Assessment of response may be difficult with current imaging techniques. The prognosis of primary bone lymphoma is generally good. Here, the current evidence for the optimal treatment of primary bone lymphoma is reviewed and questions for future investigation are addressed.
Copyright © 2012 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22402011     DOI: 10.1016/j.clon.2012.02.006

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  15 in total

1.  Primary sternum diffuse large B-cell lymphoma: A case report and review of the literature.

Authors:  Meng-Ying Tong; Xian Zhang; Zhe Yu; Xiu-Hua Sun; Shuang Li; Yang Zhang
Journal:  Oncol Lett       Date:  2015-04-16       Impact factor: 2.967

2.  ALK positive Anaplastic Large Cell Lymphoma of the Thoracic Spine.

Authors:  Gabriela Abrego; Julio García; Bruce Gilbert; Scott Forseen; Michael Toscano
Journal:  J Radiol Case Rep       Date:  2016-09-30

3.  Clinical features and outcome of primary pancreatic lymphoma.

Authors:  Eran Sadot; Joachim Yahalom; Richard Kinh Gian Do; Julie Teruya-Feldstein; Peter J Allen; Mithat Gönen; Michael I D'Angelica; T Peter Kingham; William R Jarnagin; Ronald P DeMatteo
Journal:  Ann Surg Oncol       Date:  2014-10-24       Impact factor: 5.344

4.  Primary Bone Lymphoma: A 13 Year Retrospective Institutional Analysis in the Chemo-Immunotherapy Era.

Authors:  Archana Sharma; Rayaz Ahmed; Narendra Agrawal; Jyotsna Kapoor; Anurag Sharma; Vishvdeep Khushoo; Pragya Agrawal; Dinesh Bhurani; Sumeet P Mirgh
Journal:  Indian J Hematol Blood Transfus       Date:  2020-08-08       Impact factor: 0.900

5.  18 Fluoride-fluorodeoxyglucose positron emission tomography in initial staging and response assessment of primary non-Hodgkin lymphoma of the tibia.

Authors:  Chidambaram Natrajan Balasubramanian Harisankar; Jijoe John; Thattaamuriyil Padmakumari Lekshmi; Arun Warrier
Journal:  Indian J Nucl Med       Date:  2014-10

6.  Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease.

Authors:  Patrizia Mondello; Michael Mian; Carmela Arrigo; Vincenzo Pitini
Journal:  Springerplus       Date:  2014-07-07

7.  Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement.

Authors:  Nicola Lehners; Isabelle Krämer; Maral Saadati; Axel Benner; Anthony D Ho; Mathias Witzens-Harig
Journal:  BMC Cancer       Date:  2017-02-13       Impact factor: 4.430

8.  Primary Bone Lymphoma: An Experience of a Regional Cancer Center from India.

Authors:  Rohit Mahajan; Budhi Singh Yadav; Suresh Chander Sharma; Ankita Gupta; Shikhar Kumar
Journal:  South Asian J Cancer       Date:  2021-06-12

9.  Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma.

Authors:  A Schmidt-Tanguy; R Houot; S Lissandre; J F Abgrall; P Casassus; P Rodon; B Desablens; J P Marolleau; R Garidi; T Lamy; M-P Moles-Moreau; G Damaj
Journal:  Adv Hematol       Date:  2014-03-02

10.  Primary malignant lymphoma of the talus: A case report and review of the literature.

Authors:  Shunsuke Sato; Yoichi Kaneuchi; Michiyuki Hakozaki; Hitoshi Yamada; Satoshi Kawana; Osamu Hasegawa; Shinichi Konno
Journal:  Mol Clin Oncol       Date:  2017-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.